MedTrace Logo

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

NCT00867659 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-03-27

Study results available
· View outcomes & findings →

Summary

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Cetrotide acetate

cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.

Sponsors & Collaborators

  • Virginia Center for Reproductive Medicine

    lead OTHER

Principal Investigators

  • Fady I Sharara, M.D · Virginia Center for Reproductive Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
32 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867659 on ClinicalTrials.gov